Subscriber Only
World
WHO Advises Doctors Not to Use Gilead’s Remdesivir for Covid
By
Updated on
-
U.S. FDA recently approved the drug for hospitalized patients
-
WHO experts say no evidence remdesivir improves survival
WHO Chief on Covid-19 Pandemic: We're All in This Together
The World Health Organization recommended against using Gilead Sciences Inc.’s remdesivir to treat hospitalized Covid-19 patients less than a month after U.S. regulators granted the drug a speedy approval.
“There is currently no evidence that it improves survival or the need for ventilation,” a panel of WHO-convened experts developing Covid-19 treatment guidelines said in The BMJ medical journal.
